London · Delayed Price · Currency is GBP · Price in NOK Oncoinvent ASA Statistics
Total Valuation
Oncoinvent ASA has a market cap or net worth of GBP 14.83 million. The enterprise value is 9.50 million.
| Market Cap | 14.83M |
| Enterprise Value | 9.50M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 4.48M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +367.98% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.28 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 2.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.23 |
| EV / Sales | 6.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.54 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.61 |
| Quick Ratio | 2.61 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -147.73% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 40,076 |
| Profits Per Employee | -213,902 |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 30.19 |
| Average Volume (20 Days) | 178 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncoinvent ASA had revenue of GBP 1.44 million and -7.70 million in losses. Loss per share was -6.04.
| Revenue | 1.44M |
| Gross Profit | 1.44M |
| Operating Income | -7.77M |
| Pretax Income | -7.70M |
| Net Income | -7.70M |
| EBITDA | -7.13M |
| EBIT | -7.77M |
| Loss Per Share | -6.04 |
Balance Sheet
The company has 5.44 million in cash and 448,346 in debt, with a net cash position of 4.99 million.
| Cash & Cash Equivalents | 5.44M |
| Total Debt | 448,346 |
| Net Cash | 4.99M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.01M |
| Book Value Per Share | 5.13 |
| Working Capital | 3.64M |
Cash Flow
In the last 12 months, operating cash flow was -6.05 million and capital expenditures -130,016, giving a free cash flow of -6.18 million.
| Operating Cash Flow | -6.05M |
| Capital Expenditures | -130,016 |
| Free Cash Flow | -6.18M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -538.89% |
| Pretax Margin | -533.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncoinvent ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -367.98% |
| Shareholder Yield | -367.98% |
| Earnings Yield | -51.93% |
| FCF Yield | -41.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 19, 2026. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jan 19, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
Oncoinvent ASA has an Altman Z-Score of -11.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.86 |
| Piotroski F-Score | 1 |